Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats

Journal of Nutrition

Volumn 142, Issue 6, 2012, Pages 1026-1032

  Panchal, Sunil K ^a   Poudyal, Hemant ^b   Brown, Lindsay ^a  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CASPASE 3; FRUCTOSE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYSACCHARIDE; QUERCETIN; STARCH; SUCROSE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; CELL METABOLISM; CONTROLLED STUDY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HYPERTENSION; LIPID DIET; LIVER FUNCTION; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ABDOMINAL FAT; ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIET; GENE EXPRESSION REGULATION; LIPIDS; LIVER DISEASES; MALE; METABOLIC SYNDROME X; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; RISK FACTORS;

RATTUS; RATTUS NORVEGICUS; ZEA MAYS;

EID: 84863550183     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.157263     Document Type: Article

References (43)

1. Chew GT, Gan SK,Watts GF. Revisiting the metabolic syndrome. Med J Aust. 2006;185:445-9.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
3. Sachdev MS, Riely CA, Madan AK. Nonalcoholic fatty liver disease of obesity. Obes Surg. 2006;16:1412-9.
4. Adiels M, Taskinen MR, Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep. 2008;8:60-4.
5. Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc. 2010;110:1307-21.
6. West DB, York B. Dietary fat, genetic predisposition, and obesity: lessons from animal models. Am J Clin Nutr. 1998;67:S505-12.
7. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol. 2008;24:204-9.
8. Ravussin E, Tataranni PA. Dietary fat and human obesity. J Am Diet Assoc. 1997;97:S42-6.
9. Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr Rev. 2007;65:S13-23.
10. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679-89.
11. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res. 2004;24:851-74.
12. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, et al. Quercetin reduces systolic blood pressure and plasma oxidised lowdensity lipoprotein concentrations in overweight subjects with a highcardiovascular disease risk phenotype: a double-blinded, placebocontrolled cross-over study. Br J Nutr. 2009;102:1065-74.
13. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep. 2009;61:67-75.
14. Yamamoto Y, Oue E. Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci Biotechnol Biochem. 2006;70:933-9.
15. Juźwiak S, Wojcicki J, Mokrzycki K, Marchlewicz M, Bialecka M, Wenda-Rozewicka L, Gawronska-Szklarz B, Drozdzik M. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol Rep. 2005;57:604-9.
16. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 2008;16:2081-7.
17. Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res. 2011;55:530-40.
18. Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, CefaluWT, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008;57:S39-46.
19. Abo-Salem OM, Abd-Ellah MF, Ghonaim MM. Hepatoprotective activity of quercetin against acrylonitrile-induced hepatotoxicity in rats. J Biochem Mol Toxicol. 2011;25:386-92.
20. de David C, Rodrigues G, Bona S, Meurer L, Gonzalez-Gallego J, Tunon MJ, Marroni NP. Role of quercetin in preventing thioacetamideinduced liver injury in rats. Toxicol Pathol. 2011;39:949-57.
21. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F, Ward L, et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol. 2011;57:611-24.
22. Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010;140:946-53.
23. Poudyal H, Panchal SK, Waanders J, Ward L, Brown L. Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in dietinduced obese rats. J Nutr Biochem. 2012;23:153-62.
24. Panchal SK, Poudyal H, Arumugam TV, Brown L. Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr. 2011;141:1062-9.
25. Harborne JB. The comparative biochemistry of phytoalexin induction in plants. Biochem Syst Ecol. 1999;27:335-67.
26. Grayer RJ, Harborne JB. A survey of antifungal compounds from higher plants, 1982-1993. Phytochemistry. 1994;37:19-42.
27. Galeotti F, Barile E, Curir P, Dolci M, Lanzotti V. Flavonoids from carnation (Dianthus caryophyllus) and their antifungal activity. Phytochem Lett. 2008;1:44-8.
28. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011;2011:351982.
29. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.
30. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-80.
31. Stienstra R, Duval C, Müller M, Kersten S. PPARs, obesity, and inflammation. PPAR Research. 2007;2007:95974.
32. Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003;32:855-67.
33. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32:805-22.
34. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918.
35. Salgado Júnior W, Santos JS, Sankarankutty AK, Silva Ode C. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras. 2006;21 Suppl 1:72-8.
36. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565-74.
37. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
38. Sugamura K, Keaney JF Jr. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011;51:978-92.
39. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol. 2004;37:139-43.
40. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.
41. Bachmann K, Pardoe D, White D. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect. 1996;104:400-7.
42. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-61.
43. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:S2073-85.